Therapeutic vaccine platform to boost immune responses in Tuberculosis

The goal of this SBIR Research Topic is to support small businesses in the development of new drug classes with novel mechanisms of action for HIV, Hepatitis B (HBV), and Tuberculosis (Mtb). HBV and Mtb drugs must be compatible with current antiretroviral therapy regimens. The goal of this contract is to build a prototype mRNA vaccine containing Mtb-antigens as a safe and effective multivalent therapeutic vaccine against tuberculosis. Project Number: 75N93025C00024-0-9999-1 | Fiscal Year: 2025 | NIH Institute/Center: National Institute of Allergy and Infectious Diseases (NIAID) | Principal Investigator: KAREN ANTHONY | Institution: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT | Award Amount: $599,471 | Activity Code: N43 View on NIH RePORTER: https://reporter.nih.gov/project-details/75N93025C00024099991